Clinical trials: Atorvastatin
Hyperlipidemia
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in…
- Trial name
- NCT02659397
- Testing
- ETC-1002, Atorvastatin
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Esperion Therapeutics, Inc.
Diabetes, Type 2
Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
The AFORRD trial is asking three important questions: What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the…
- Trial name
- AFORRD (NCT00141232)
- Testing
- Atorvastatin and Omega-3 fatty acids
- Where
- 59 sites in United Kingdom
- Volunteers
- 810 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
CKD-337(2) Drug-drug Interaction Study
The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acid.
- Trial name
- NCT02422030
- Testing
- Lipitor Tab. 40mg, Trilipix 135mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and
- Trial name
- NCT07362030
- Testing
- RAY1225, atorvastatin calcium tablet, Metformin Tablets
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Healthy
Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor 20mg/Glucophage SR 750mg
This study is designed to evaluate safety and pharmacokinetic properties of the two treatments, the administration of CJ-30056 and the co-administration of atorvastatin 20mg and metformin SR 750mg, in healthy volunteers.
- Trial name
- NCT02378441
- Testing
- Atorvastatin 20mg and Metformin SR 750mg, CJ-30056 20/750mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet
A phase I, Open-label, Randomized, Single-dose, 2 x 2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet and Coadministration of Fimasartan and Atorvastatin as Individual Tablets in…
- Trial name
- NCT02566187
- Testing
- Fimasartan/Atorvastatin Combination Tablet, Fimasartan, Atorvastatin
- Where
- South Korea
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pediatric Heterozygous Hypercholesterolemia
8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
- Trial name
- NCT00739999
- Testing
- Atorvastatin
- Where
- 3 sites in Canada, Greece and 1 more
- Volunteers
- 39 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration
The objective of this study is to assess the effectiveness of an atorvastatin treatment regimen involving starting doses between 10 and 80 mg, followed by a single-step titration (except for subjects started at 80mg), if required
- Trial name
- CANACTFAST (NCT00150371)
- Testing
- atorvastatin
- Where
- 84 sites in Canada
- Volunteers
- 1,100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥ 100 mg/dL (≥…
- Trial name
- NCT01288443
- Testing
- Alirocumab, Atorvastatin
- Where
- 38 sites in United States
- Volunteers
- 183 people
- Sponsor
- Sanofi
Healthy
Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers
To investigate the bioavailability of dabigatran with and without concomitant administration of atorvastatin and the bioavailability of atorvastatin with and without concomitant administration of dabigatran etexilate
- Trial name
- NCT02171039
- Testing
- Dabigatran, Atorvastatin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis
This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).
- Trial name
- NCT00103974
- Testing
- BHT-3009-01
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bayhill Therapeutics
Hyperlipidemia
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Trial name
- NCT00138762
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 154 sites in United States, Belgium and 6 more
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01812707
- Testing
- Alirocumab, Atorvastatin
- Where
- 4 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Atherosclerotic Carotid Disease, Atheroma
Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging
A new way of scanning narrowing in the arteries (main blood vessels) caused by fatty deposits known as plaques has been developed. Heart attacks and strokes occur when plaques become inflamed, depending on the artery affected.
- Conditions
- Atherosclerotic Carotid Disease, Atheroma, Atherosclerosis
- Trial name
- NCT00368589
- Testing
- atorvastatin
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Dyslipidaemia
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in African American subjects with hypercholesterolemia.
- Trial name
- ARIES (NCT00653744)
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemia (Fredrickson Type Ⅱa), Dyslipidemia (Fredrickson Type Ⅱb)
CKD-337 Drug Interaction Study
The purpose of this study is to evaluate a pharmacokinetic drug interaction between atorvastatin and fenofibrate in healthy subjects.
- Trial name
- NCT02066207
- Testing
- Fenofibrate, Atorvastatin
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
A study to evaluate impact of Obicetrapib on PK levels of Atorvastatin and Rosuvastatin
- Trial name
- NCT06081166
- Testing
- Obicetrapib, Atorvastatin Calcium, Rosuvastatin Calcium
- Where
- Canada
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- NewAmsterdam Pharma
Angina
Double Blind Atorvastatin Amlodipine Study
To evaluate and compare the safety and efficacy of amlodipine, atorvastatin and the combination in patients with symptomatic myocardial ischemia.
- Trial name
- DUAAL (NCT00159718)
- Testing
- amlodipine, atorvastatin
- Where
- 33 sites in Croatia, Czechia and 9 more
- Volunteers
- 360 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917644
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.